Nonagen Bioscience Corporation has developed a multiplex urinary assay (Oncuria™ - see 'Products') for the non-invasive detection and monitoring of bladder cancer. The performance of the assay is being tested in a number of clinical trials - see details of ongoing trials below:

1.  A Novel Multiplex ELISA Assay for evaluating Patients with Microscopic Hematuria for Bladder Cancer, NCT #03193541; Locations Dallas, TX and Honolulu, HI

2.  A Novel Multiplex ELISA Assay for evaluating Patients with Gross Hematuria for Bladder Cancer, NCT #03193528; Locations Dallas, TX and Honolulu, HI

3.  A Novel Multiplex ELISA Assay for Surveilling Patients with History of Bladder Cancer, NCT #03193515; Locations Dallas, TX and Honolulu, HI